Magnesium Salicylate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Magnesium Salicylate
- Magnesium Salicylate: From Oral Analgesic Products (Indication Not Listed) to Spondyloarthropathy, Susceptibility To
Magnesium Salicylate: From Oral Analgesic Products (Indication Not Listed) to Spondyloarthropathy, Susceptibility To
One-Sentence Summary
Magnesium salicylate is a salicylate (NSAID-class) compound sold in the US in oral products, several named for back pain relief. The TxGNN model predicts it may be effective for spondyloarthropathy, susceptibility to, but no clinical trials and no publications currently support this prediction. It is a model-only signal (Evidence Level L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the regulatory data (product names such as “Back Pain Relief” suggest pain relief) |
| Predicted New Indication | Spondyloarthropathy, susceptibility to |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 8 licenses (5 shown below) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, magnesium salicylate is a non-acetylated salicylate in the NSAID class. NSAIDs inhibit COX and prostaglandin synthesis and are used for pain and inflammation. Non-acetylated salicylates inhibit COX only weakly.
“Spondyloarthropathy, susceptibility to” describes a genetic susceptibility phenotype, not a directly treatable clinical condition. Any link to the drug would be indirect, through the class effect of NSAIDs on the symptoms of inflammatory spondyloarthritis. The score of 99.98% therefore should not be read as evidence of efficacy.
The other predicted indications do not clarify the picture:
- Ankylosing spondylitis (rank 5, score 99.96%) is the most clinically meaningful candidate. NSAIDs are established symptomatic therapy, so it is classed as L4 (a research question). However, no drug-specific trial or publication was supplied, and efficacy relative to standard NSAIDs is unproven.
- Rare skeletal and developmental disorders (for example brachyolmia, pseudoachondroplasia, acromesomelic dysplasia) show no plausible mechanism. These high scores most likely reflect knowledge-graph proximity between skeletal phenotypes, not pharmacology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M013 | Percogesic | Tablet, coated | Not listed |
| M013 | Maximum Strength Backache Relief | Capsule, coated | Not listed |
| M013 | Medique Back Pain Relief | Tablet, film coated | Not listed |
| part343 | Doans | Tablet | Not listed |
| M013 | Medique at Home Back Pain Relief | Tablet, film coated | Not listed |
All listed products are oral formulations.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials, no literature, and no confirmed mechanism. The top-ranked disease is a genetic susceptibility phenotype and cannot be treated directly. The only clinically plausible neighbour, ankylosing spondylitis, is supported only by the general NSAID class effect.
To proceed, the following is needed:
- Package insert warnings and contraindications (blocking for safety screening)
- Mechanism of action data for magnesium salicylate
- The approved indication text for the US products
- A focused literature and trial search on magnesium salicylate in ankylosing spondylitis or axial spondyloarthritis, including a comparison against standard NSAIDs
- Route compatibility assessment (currently pending)
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.